MDM4 and prostate adenocarcinoma: Moreover, the upregulated expression of MDM4 was often accompanied by adverse clinical features, such as AFP > 400 ng/ml in LIHC, CEA > 5 ng/ml in COADREAD, and Gleason score > 8 in PRAD (Fig. 2G–I).